Evonik stock slips 2.15% from morning quote

Published on 11/09/2026 at 17:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evonik stock moved lower after the morning quote. Management still expects full-year operating earnings in the upper half of its range.

Operating momentum meets restructuring costs

Evonik expects 2026 adjusted EBITDA to land in the upper half of its existing range.
Management expects fourth-quarter earnings to exceed the prior-year level.
A restructuring provision continues to weigh on reported net income.

Evonik, DE000EVNK013, Illustration mit AI erstellt.

What happened: Evonik stock traded at 20.93 euros on Lang & Schwarz at 17:12 CET on Monday, November 9, 2026, 0.90 percent below the Xetra close of Friday, November 6. The quote was 2.15 percent below the 21.39 euros reported in the morning, giving the second main report a fresh market development.

Evonik said in its investor-relations update on November 3 that strong third-quarter earnings had increased confidence in the 2026 outlook. Management expects adjusted EBITDA to reach the upper half of its existing 2.0 billion to 2.2 billion euro range.

What remains in focus

The company also expects fourth-quarter earnings to exceed the prior-year level. That outlook keeps operating performance at the center of the investment case as Evonik works through restructuring measures and a more demanding chemical-market environment.

The morning report highlighted that a provision linked to the extended efficiency program weighed on reported net income despite the stronger operating trend. For investors, the combination leaves a contrast between improving operating earnings and ongoing transformation costs.